Therapy of Chronic Myelogenous Leukemia with Interferon

References

• Fialkow P J, Jacobson R J, Papayannopoulou T. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Nowell P C, Hungerford D A. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1197
   Web of Science ®Google Scholar
• Rowley J D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–297
   PubMed Web of Science ®Google Scholar
• Koeffler H P, Golde D W. Chronic myelogenous leukemia new concepts. N Engl J Med 1981; 304: 1201–1209, 1269–1274
   PubMed Web of Science ®Google Scholar
• Coloumbel L, Kalousek D K, Eaves C J, et al. Long-term culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl Med 1983; 308: 1493–1498
   PubMed Web of Science ®Google Scholar
• Isaacs A, Lindenmann J. Virus Interference. 1. The interferon. Proc R Soc Lond (Biol) 1957; 147: 258–267
   PubMed Web of Science ®Google Scholar
• The Interferon System, W EI Stewart. Springer-Verlag, New York 1979
   Google Scholar
• Borden E C, Fall L, Interferons A. Biochemical, cell growth inhibitory, and immunological effects. Prog Hematol 1981; 350: 1–64
   Google Scholar
• Vilcek J, Gray P W, Rinderknecht E, . Interferon- gamma: A lymphokine for all seasons. Lymphokines, E Pick, et al. Academic, Orlando 1685; vol. 12.: 1–32
   Google Scholar
• Goepfert J, Sessions R B, Gutterman J U, et al. Leukocyte interferon in patients with juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol 1982; 91: 431–435
   PubMed Web of Science ®Google Scholar
• Quesada J R, Reuben F, Manning J T, et al. Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984; 310: 15–18
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Krown S E, Real F X, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983; 308: 1071–1076
   PubMed Web of Science ®Google Scholar
• Gutterman J U, Blumenschein G R, Alexanian R, et al. Leukocyte interferon-induced tumor regression human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980; 93: 399–406
   PubMed Web of Science ®Google Scholar
• Foon K A, Sherwin S A, Abrams P G, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukoctye A interferon. N Engl J Med 1984; 311: 1148–1152
   PubMed Web of Science ®Google Scholar
• Quesada J, Swanson D A, Trindade A, et al. Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 1983; 43: 940–947
   PubMed Web of Science ®Google Scholar
• Czarniecki C W, Fennie C W, Powers D B, et al. Synergistic antiviral and antiproliferative activities of E. coli derived human alpha, beta, and gamma interferon. J Virol 1984; 49: 490–496
   PubMed Web of Science ®Google Scholar
• Verma D S, Spitzer G, Gutterman J U, et al. Human leukocyte interferon blocks granulopoietic differentiation. Blood 1978; 54: 1423–1427
   Web of Science ®Google Scholar
• Neuman H A, Fauser A A. Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 1982; 10: 587–590
   PubMed Web of Science ®Google Scholar
• Oladipupo-Williams C K, Svet-Moldavskaya I, Bilchek J. Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 1981; 38: 356–360
   PubMed Web of Science ®Google Scholar
• Kimpel G R, Fleischmann W R, Jr, Klimpel K D. Gamma interferon (IFN-gamma) andd IFN-alpha/beta suppress murine myeloid colony formation (CFU-C): Magnitude of suppression is dependent upon level of colony-stimulating factor (CSF)1. J Immunol 1982; 129: 76–79
   PubMed Web of Science ®Google Scholar
• Raefsky E L, Platanias L C, Zoumbos N C, Young N S. Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 1985; 135: 2507–2512
   PubMed Web of Science ®Google Scholar
• Talpaz M, McCredie K B, Mavligit G M, Gutterman J U. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689–692
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H M, McCredie K B, et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280–1288
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Smith T L, McCredie K B, et al. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326–1335
   PubMed Web of Science ®Google Scholar
• Monfardini S, Gee T, Fried J, Clarkson B. Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis. Cancer 1973; 31: 492–501
   PubMed Web of Science ®Google Scholar
• Niederle N, Doberauer C, Kloke O, et al. Treatment of chronic myelogenous leukemia with recombinant interferon-alpha (IFN-alpha2B) (abstr). Proc Am Soc Clin Oncol 1986; 5, 236 #925
   Google Scholar
• Morra I, Alimena G, Liberati A M, et al. Recombinant alpha-2 interferon in the treatment of chronic myelogenous leukemia (CML) (abstr). Proc Am Soc Clin Oncol 1987; 6: 145
   Google Scholar
• Rowley J D. Ph-positive leukemia, including chronic myelogenous leukemia. Clin Hematol 1980; 9: 55–81
   PubMedGoogle Scholar
• Talpaz M, Trujillo J M, Hittelman W N, et al. Suppression of colonal evolution in two chronic myelogenous leukemia patients treated with leukocyte interferon. Br J Hematol 1985; 60: 619–624
   PubMed Web of Science ®Google Scholar
• Talpaz M, Gutterman J U, Kantarjian H, Trujillo J. Development of a secondary Ph clone in a patient with chronic myelogenous leukemia and its suppression with alpha interferon. Cancer Bull 1986; 38: 267–268
   Google Scholar
• McGlave P, Mamus S, Vilen B, Dewald G. Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp Haematol 1987; 15: 331–335
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Talpaz M, Kantarjian H, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 1987; 70: 943–947
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Quesada J R, Talpaz M, et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 1986; 4: 1101–1109
   PubMed Web of Science ®Google Scholar
• Branca A A, Banglioni C. Evidence that types I and II interferons have different receptors. Nature 1981; 294: 768–770
   PubMed Web of Science ®Google Scholar
• Mason J E, DiVita V Y, Canellos G P. Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 1974; 44: 483–487
   PubMed Web of Science ®Google Scholar
• Salem H H, Van Der Weyden M B, Koutts J, Pirkin B G. Leg pain and platelet aggregates in thrombocythemic myeloproliferative disease. J Am Med Assoc 1980; 244: 1122–1123
   PubMed Web of Science ®Google Scholar
• Talpaz Mavligit M. G, Keating M, et al. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 1983; 99: 789–792
   PubMed Web of Science ®Google Scholar
• Smalley R V, Vogel J, Huguley C M, et al. Chronic granulocytic leukemia: Cytogenetic conversion of the bone marrow with cycle-specific chemotherapy. Blood 1977; 50: 107–111
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Vellekoop L, McCredie K B, et al. Intensive chemotherapy (ROAP 10) and splenectomy in patients with Philadelphia-positive chronic myelogenous leukemia. J Clin Oncol 1985; 3: 192–200
   PubMed Web of Science ®Google Scholar
• Cunningham I, Gee T, Dowling M, et al. Results of treatment of Ph1 + chronic myelogenous leukemia with an intensive regimen (L-5 protocol). Blood 1979; 53: 375–395
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, Keating M, et al. Therapy of Philadelphia (Ph)-positive chronic myelogenous leukemia (CML) with initial chemotherapy (DOAP) followed by maintenance with human leukocyte alpha interferon (abstr). Am Soc Hematol 1986; 68(776)224a
   Google Scholar
• Bergsagel D E, Haas R H, Messner H A. Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 1986; 13: 29–34
   PubMed Web of Science ®Google Scholar
• Newland A C, Jones L, Mir N, Slocombe G W. Alpha 2 interferon in chronic myeloid leukaemia following relapse post-allogeneic transplant. Br J Hematol 1987; 66: 141–148
   PubMed Web of Science ®Google Scholar
• Quesada J R, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4: 234–243
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Rhode M F, Quesada J R, et al. Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med 1986; 164: 1093–1101
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Talpaz M, Quesada J R, et al. Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. J Am Med Assoc 1985; 254: 1353–1355
   PubMed Web of Science ®Google Scholar
• Taetle R, Buick R N, McCulloch E A. Effect of interferon on colony-formation in culture by blast cell progenitors in acute myeloblastic leukemia. Blood 1980; 56: 549–552
   PubMed Web of Science ®Google Scholar
• Talpaz M, Spitzer G, Hittelman W, et al. Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon treated chronic myelogenous leukemia patients. Exp Hematol 1986; 14: 669–681
   Google Scholar
• Friedman R M. Interferon binding: The first step in establishing on antiviral activity. Science 1967; 156: 1760–1861
   PubMed Web of Science ®Google Scholar
• Maxwell B L, Talpaz M, Gutteman J U. Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon alpha therapy. Int J Cancer 1985; 36: 23–28
   PubMed Web of Science ®Google Scholar
• Rosenblum M G, Maxwell B L, Talpaz M, et al. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: Correlation with receptor binding and induction of 2;5;-oligoadenylate synthetase. Cancer Res 1986; 46: 4848–4852
   PubMed Web of Science ®Google Scholar
• Brodsky I, Hubbell H R, Strayer D R, Gillespie D H. Implications of retroviral and oncogene activity in chronic myelogenous leukemia. Cancer Genet Cytogenet 1987; 26: 15–23
   PubMed Web of Science ®Google Scholar
• Kleinerman E S, Kurzrock R, Wyatt D, et al. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with recombinant gamma-interferon. Cancer Res 1986; 46: 5401–5405
   PubMed Web of Science ®Google Scholar